J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Posvar, E.
Right arrow Articles by Sedman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Posvar, E.
Right arrow Articles by Sedman, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

EL Posvar, LL Radulovic, Cilla DD Jr, LR Whitfield, and AJ Sedman

Tolerance and pharmacokinetics after single-dose administration of atorvastatin, an investigational inhibitor of HMG-CoA reductase, were examined in 22 healthy volunteers in a three-period, partially-blinded study. Participants received capsule and solution doses of atorvastatin (0.5 to 120 mg) and placebo at weekly intervals. Atorvastatin was well tolerated at doses as high as 80 mg. The adverse event profile was similar after administration of atorvastatin capsules and placebo. Atorvastatin solution was slightly less well tolerated. The most common side effect after administration of capsules and solution was headache, followed by sporadic reports of diarrhea, flatulence, and nausea. At the 120-mg solution dose, one participant experienced mild, transient restlessness, euphoria, and mental confusion that were considered to be dose-limiting side effects. Mean concentrations of atorvastatin, maximum concentration (Cmax), and area under the concentration-time curve from time 0 to the time of the last detectable concentration (AUCo-tldc) increased with increasing dose. Plasma elimination half-life (t1/2) ranged from 14.7 to 57.6 hours. The bioavailability of atorvastatin capsules was similar to that of solution. These results suggest that atorvastatin is well tolerated after single doses as high as 80 mg, and may require administration only once daily.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
H. Savini, J. B. Souraud, S. Briolant, E. Baret, R. Amalvict, C. Rogier, and B. Pradines
Atorvastatin as a Potential Antimalarial Drug: In Vitro Synergy in Combinational Therapy with Dihydroartemisinin
Antimicrob. Agents Chemother., February 1, 2010; 54(2): 966 - 967.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. A. Pham, C. J. L. la Porte, L. S. Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner, et al.
Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4385 - 4392.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. R. Coward, A. Marei, A. Yang, M. M. Vasa-Nicotera, and S. C. Chow
Statin-Induced Proinflammatory Response in Mitogen-Activated Peripheral Blood Mononuclear Cells through the Activation of Caspase-1 and IL-18 Secretion in Monocytes
J. Immunol., May 1, 2006; 176(9): 5284 - 5292.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. E Sipe, R. J Jones, and G. H Bokhart
Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction
Ann. Pharmacother., June 1, 2003; 37(6): 808 - 811.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. L. Lins, K. E. Matthys, G. A. Verpooten, P. C. Peeters, M. Dratwa, J.-C. Stolear, and N. H. Lameire
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients
Nephrol. Dial. Transplant., May 1, 2003; 18(5): 967 - 976.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein
Risk for Myopathy With Statin Therapy in High-Risk Patients
Arch Intern Med, March 10, 2003; 163(5): 553 - 564.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
Y. Majlesi, P. Samorapoompichit, A. W. Hauswirth, G.-H. Schernthaner, M. Ghannadan, M. Baghestanian, A. Rezaie-Majd, R. Valenta, W. R. Sperr, H.-J. Buhring, et al.
Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3
J. Leukoc. Biol., January 1, 2003; 73(1): 107 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. H. Wagner, M. Gebauer, B. Guldenzoph, and M. Hecker
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase-Independent Inhibition of CD40 Expression by Atorvastatin in Human Endothelial Cells
Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1784 - 1789.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Clinical Pharmacology